Characterization and expression of ATP P2X4 receptor from embryonic chick skeletal muscle
Article first published online: 26 JUL 2001
Copyright © 2001 Wiley-Liss, Inc.
Drug Development Research
Volume 53, Issue 1, pages 22–28, May 2001
How to Cite
Bo, X., Liu, M., Schoepfer, R. and Burnstock, G. (2001), Characterization and expression of ATP P2X4 receptor from embryonic chick skeletal muscle. Drug Dev. Res., 53: 22–28. doi: 10.1002/ddr.1165
- Issue published online: 26 JUL 2001
- Article first published online: 26 JUL 2001
- Manuscript Accepted: 17 APR 2001
- Manuscript Received: 1 MAR 2001
- The Wellcome Trust
- P2X receptor;
- skeletal muscle
Previous pharmacological experiments have indicated the existence of ATP P2X receptors in chick embryonic skeletal muscles. In this study we cloned a P2X4-like cDNA encoding a protein of 385 amino acids, which shares 75% and 76% identity with rat and human P2X4 receptors, respectively. Functional studies of this cP2X4 receptor expressed in Xenopus oocytes showed that ATP induced a fast inward current, which was partially desensitized upon prolonged application of ATP. The ATP-induced currents were concentration-dependent, with an EC50 of 9.5 μM. Adenosine 5′-O-(thio)triphosphate and 2-methylthioATP very weak agonists. α,β-methyleneATP was almost inactive. In contrast to their potentiating effects on recombinant rat P2X4 receptors, both suramin and pyridoxalphosphate-6-azophenyl-2′,4′-disulfonic acid partially blocked ATP-induced currents. TrinitrophenylATP was able to block ATP-induced response completely, with an IC50 of 4.7 μM. Northern blot and RT-PCR analysis showed that cP2X4 mRNAs were mainly expressed in skeletal muscle, brain, and gizzard of day 10 chick embryos. Lower levels of expression were also detected in liver, heart, and retina. Whole-mount in situ hybridization showed that cP2X4 mRNAs were expressed in the brain, spinal cord, notochord, gizzard, and skeletal muscle. The physiological functions of cP2X4 receptors in embryonic skeletal muscle remain unclear at present. Drug Dev. Res. 53:22–28, 2001. © 2001 Wiley-Liss, Inc.